bluebird bio (BLUE) News Today

bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 41,140,000 shares, a growth of 32.2% from the July 31st total of 31,130,000 shares. Based on an average trading volume of 6,720,000 shares, the short-interest ratio is currently 6.1 days.

bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Stock analysts at William Blair decreased their Q2 2024 earnings estimates for bluebird bio in a research report issued to clients and investors on Wednesday, August 14th. William Blair analyst S. Corwin now anticipates that the biotechnology compa

Bank of America reduced their price objective on shares of bluebird bio from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Thursday.

Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 price target on shares of bluebird bio in a research note on Thursday.

Shares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been given a consensus rating of "Hold" by the eleven research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation

Vanguard Group Inc. raised its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 19.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,498,460 shares of the biotechnology company's stock after buying an additional 1

bluebird bio (NASDAQ:BLUE) Stock Passes Below 200 Day Moving Average of $1.10

BNP Paribas Financial Markets trimmed its stake in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 80.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,100 shares of the biotechnology company's stock after sell

bluebird bio (NASDAQ:BLUE) Stock Passes Above Fifty Day Moving Average of $0.96

bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) saw a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 29,120,000 shares, a decrease of 7.8% from the May 15th total of 31,600,000 shares. Based on an average trading volume of 6,540,000 shares, the days-to-cover ratio is presently 4.5 days.

HBK Investments L P acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,500,000 shares of the biotechnology company's stock, valued at approximately $2,070

Masters Capital Management LLC acquired a new position in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,000,000 shares of the biotechnology company's stock, valued

Ghisallo Capital Management LLC acquired a new stake in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,150,000 shares of the biotechnology company's stock, valued at app

Vestal Point Capital LP purchased a new stake in shares of bluebird bio, Inc. (NASDAQ:BLUE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,150,000 shares of the biotechnology company's stock, valued at